Key role of the RhoA/Rho kinase system in pulmonary hypertension.
Pulmonary hypertension (PH) is a general term comprising a spectrum of pulmonary hypertensive disorders which have in common an elevation of mean pulmonary arterial pressure (mPAP). The prototypical form of the disease, termed pulmonary arterial hypertension (PAH), is a rare but lethal syndrome with a complex aetiology characterised by increased pulmonary vascular resistance (PVR) and progressive elevation of mPAP; patients generally die from heart failure. Current therapies are inadequate and median survival is less than three years. PH due to chronic hypoxia (CH) is a condition separate from PAH and is strongly associated with chronic obstructive pulmonary disease (COPD). An early event in the pathogenesis of this form of PH is hypoxic pulmonary vasoconstriction (HPV), an acute homeostatic process that maintains the ventilation-perfusion ratio during alveolar hypoxia. The mechanisms underlying HPV remain controversial, but RhoA/Rho kinase (ROK)-mediated Ca²+-sensitisation is considered important. Increasing evidence also implicates RhoA/ROK in PASMC proliferation, inflammatory cell recruitment and the regulation of cell motility, all of which are involved in the pulmonary vascular remodelling occurring in all forms of PH. ROK is therefore a potential therapeutic target in treating PH of various aetiologies. Here, we examine current concepts regarding the aetiology of PAH and also PH due to CH, focusing on the contribution that RhoA/ROK-mediated processes may make to their development and on ROK inhibitors as potential therapies.
Connolly
Michelle J
MJ
Division of Asthma, Allergy and Lung Biology, School of Medicine, King's College London, United Kingdom. michelle.connolly@kcl.ac.uk
Aaronson
Philip I
PI
D000818:Animals; D052006:Bone Morphogenetic Protein Receptors, Type II / Q000235:genetics; D049109:Cell Proliferation; D019332:Endothelin-1 / Q000502:physiology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000209:etiology*; D000860:Hypoxia / Q000150:complications; D009131:Muscle, Smooth, Vascular / Q000502:physiology; D050778:NFATC Transcription Factors / Q000502:physiology; D012701:Serotonin / Q000502:physiology; D014661:Vasoconstriction; D054460:rho-Associated Kinases / Q000502:physiology*; D020742:rhoA GTP-Binding Protein / Q000037:antagonists & inhibitors / Q000502:physiology*
D019332:Endothelin-1; D050778:NFATC Transcription Factors; D012701:Serotonin; D054460:rho-Associated Kinases; D052006:Bone Morphogenetic Protein Receptors, Type II; D020742:rhoA GTP-Binding Protein